Why this ASX microcap skyrocketed 190% on Tuesday

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is up 190% on news of a spinal injury breakthrough

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price skyrocketed 190% on Tuesday after news that the company's flagship drug EmtinB was part of a successful study into the treatment of Alzheimer's disease as well as a range of other neurological conditions such as spinal injuries, Multiple Sclerosis, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

NSB shares had been in a trading halt since Monday, but upon release if its results, the NSB share price has risen from 14 cents per share to 42 cents at close of trading yesterday, a rise of around 190%.

Neuroscientific Biopharmaceuticals stated in its release to the ASX that "the company is pleased to report the results of a breakthrough study that paves the way for a new effective way to treat Alzheimer's, our lead indication. The study also points towards ability of EmtinB to be a powerful avenue to help patients by developing drugs for several other neurodegenerative diseases".

On the potential success of EmtinB, the company also stated that "the highest dose of EmtinB significantly stimulated regeneration of nerve cells by more than 300% in comparison to controls incubated with sterile water".

Neuroscientific Biopharmaceuticals also claims that EmtinB is twice as effective as the current market-leading drug for Multiple Sclerosis, of which $4 billion is sold annually.  The company has ongoing pre-clinical efficacy, safety and toxicology studies and has informed the market to expect results from these soon.  Although the study so far had been testing the EmtinB product on rat nerve cells, the first human studies will begin this quarter.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

4 ASX All Ords shares rocketing over 10% today

These shares started the week with a bang. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Market News

Here are the top 10 ASX 200 shares today

ASX investors endured a rough start to the week today...

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Bell Potter names more of the best ASX stocks to buy

The broker has good things to say about these stocks.

Read more »

Man with rocket wings which have flames coming out of them.
Mergers & Acquisitions

Guess which ASX stock just rocketed 40% on takeover news

A colossal company finds value in the small end of our ASX town.

Read more »

Happy diverse colleagues or team of people give high five together to celebrate great teamwork and results.
Share Gainers

Why Black Cat, Dicker Data, Novonix, and Pointsbet shares are racing higher

These shares are starting the week with a bang. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Champion Iron, Endeavour, Infomedia, and Resolute Mining shares are sinking today

These shares are starting the week in the red. But why?

Read more »

Couple look at a bottle of wine while trying to decide what to buy.
Consumer Staples & Discretionary Shares

Guess which ASX 200 stock just hit an all-time low following a profit warning

Higher costs and flat sales are weighing on this blue-chip stock.

Read more »